{"id":"tp-39679","type":"article-newspaper","title":"Alnylam Reports Mutant Protein Reduction in Highest-Dose Trial Group","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/39679","datePublished":"2026-10-24T05:22:37.000Z","dateModified":"2026-10-24T05:22:37.000Z","language":"en","abstract":"The highest-dose group had a 60% to 64% mean reduction in spinal-fluid mutant huntingtin three months after one dose, but the early study has not shown disease slowing.","section":"Business","references":[]}